The reputation of a Canadian cannabis company has fallen even further with the news of a million dollar product return in the midst of a growing scandal.

CannTrust Holdings (NYSE:CTST,TSX:TRST) announced Monday (August 19) that the Ontario Cannabis Store (OCS) has returned all of the company’s products, worth C$2.9 million.

The crown corporation tasked with the distribution of cannabis products in the province has deemed that certain CannTrust goods are “non-conforming products” that do not comply with its master cannabis supply agreement with CannTrust.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

CannTrust told shareholders it will adhere to the terms of the master agreement, through which the OCS holds the right to return any products deemed non-conforming at the company’s expense.

In an email to the Investing News Network (INN), an OCS spokesperson said that the decision to return the product is “consistent with the OCS’ obligation to operate its business in a responsible manner.”

In its statement, CannTrust notes that the OCS operates independently of Health Canada, the country’s federal cannabis regulator, which has not ordered a recall of the company’s cannabis products.

As the cannabis industry continues to search for valid metrics to compare companies, provincial deals for the distribution of recreational product have gained prominence as a way to examine market presence.

The OCS has now pulled all options for CannTrust products from its website.

In an email response to INN, a CannTrust spokesperson said the company does not know when exactly the OCS will be returning the physical cannabis product.

The Canadian producer confirmed that the product being returned was grown in its unlicensed rooms. According to the spokesperson, all the product sent to the OCS had “met Health Canada standards.”

When asked where the returned product will be allocated, the CannTrust spokesperson told INN the firm is currently reviewing the purpose of the items, but is already considering a clearance by performing bulk sales and holding it under licensed storage.

The company’s share price has dropped drastically since news of its non-compliance broke last month. In Toronto, the company opened at C$2.72 on Monday, a decrease of almost 58 percent since it closed at C$6.46 on July 5, before the company disclosed Health Canada’s findings.

New York is a similar tale. On Monday, shares of the company opened at a price of US$2.09 on the NYSE, a drop of almost 58 percent since July 5, when it closed at US$4.94. Near the end of the trading session, shares of the company were down 4.29 percent at a price of US$2.01.

This follows a management cease trade order (MCTO) issued by the Ontario Securities Commission that the company announced on Thursday (August 15). The order prevents CannTrust executives from trading in securities of the company until two days after the company files all the necessary documents, including CannTrust’s Q2 financial report.

The Canadian company elected to file the MCTO because it would be unable to meet the August 14 deadline to file its interim financial reports for the three and six month periods that ended on June 30.

The beleaguered Ontario-based cannabis company has been in the middle of a developing scandal since the unlicensed growing of cannabis in five unlicensed rooms at its facility in Pelham, Ontario, was exposed, resulting in a non-compliant rating from Health Canada.

Following the initial reveal from the cannabis producer, Health Canada placed a hold on 5,200 kilograms worth of dried cannabis product, with CannTrust itself also holding back 7,500 kilograms of marijuana product. The held cannabis is worth over C$69 million based on the average sale price of C$5.47 per gram that was reported in the company’s Q1 results.

In the fallout, an internal investigation was launched as it was found that false walls were hung to hide the unlicensed rooms during routine Health Canada inspections.

The scandal grew when BNN Bloomberg reported that CannTrust executives, including former CEO Peter Aceto and Chairman Eric Paul, were aware of the unlicensed rooms and told employees to “continue as planned” with regards to the illegal growing.

The news resulted in Aceto’s firing and the requested resignation of Paul. Robert Marcovitch, chair of the special committee charged with investigating the matter, was appointed to the role of interim CEO.

Analysts on TipRanks have the company listed as a “hold” with a price target of C$7, a 251 percent upside over the current share price.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

HempFusion Wellness Inc . (TSX:CBD.U) (US:CBDHF) (FWB:8OO) (“ HempFusion ” or the “ Company ”), a leading health and wellness company offering premium probiotic supplements and products containing CBD, announced today it will report its financial results for the first quarter ended March 31, 2021 at 4 p.m., Eastern Time, on Monday, May 17, 2021 followed by a 4:15 p.m., Eastern Time conference call and webcast with a question-and-answer session.

To participate in the call, please dial 888-506-0062. For international callers, dial 973-528-0011. Use Participant Code: 795055

Keep reading... Show less

Partnership Aimed at Delivering Psychedelic
Capsule for Dosing Study in Human Clinical Trial

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, and Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, have met another early milestone in the development of an initial all natural psilocybin extract.

Keep reading... Show less

Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, and Numinus Wellness Inc. (“Numinus“) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, have met another early milestone in the development of an initial all natural psilocybin extract.

Optimi and Numinus, through Impact Clinical Trials Accelerator at the University of Calgary (“Impact”), have submitted a pre-clinical trial application to Health Canada for review and comment. Meanwhile, cultivation, research, formulation, and continuous validation studies to produce the investigational psilocybin extract for trial continue at the Health Canada-licensed Numinus lab in British Columbia, Canada.

Keep reading... Show less

Poised for Rapid Growth in Europe’s Largest Medical Cannabis Market

Curaleaf Holdings, Inc. (CSE: CURA OTCQX: CURLF) (“Curaleaf” or the “Company”) a leading international provider of consumer products in cannabis, today announced that wholly owned Curaleaf International subsidiary Adven GmbH (“Adven”) has launched its own range of medical cannabis products in Germany Europe’s largest medical cannabis market.  The initial launch of a high THC oil product aims to meet immediate patient demand and will be extended over the course of the year to incorporate a number of different strengths and THCCBD formulations in both oil and flower formats, addressing a wide range of patient needs. Germany is Europe’s largest medical cannabis market and is expected to be worth US$2.1 billion by 2025 1 .

Keep reading... Show less

After announcing placements of Fit Soda™ in well-known regional grocery chains such as HEB and Sprouts, Koios is pleased to announce that its Fit Soda™ functional beverage is now available in all Food Lion supermarkets, a chain which operates more than 1,100 grocery stores in the eastern United States. As the sugar-free beverage category continues to grow, Coca-Cola recently announced its prediction that its “Coke Zero Sugar” variety will be the firm’s biggest driver of growth in 2021 and beyond. Based on these industry trends, Koios’ objective is to strategically grow the market presence of Fit Soda™, which sold approximately 700,000 units in 2020, its first full calendar year on the market.

Koios Beverage Corp. (CSE: KBEV; OTC: KBEVF) (the “Company” or “Koios”) is pleased to announce that as of Monday, May 10, 2021 all four flavours of Fit Soda ™ are being carried in more than 1,100 supermarkets operated by Food Lion LLC (“Food Lion”), a multistate grocery chain based in Salisbury, North Carolina. Since November 2020, the Company has placed its Fit Soda ™ functional beverage product with several other regional chains across the United States to include HEB (as announced in a November 4, 2020 press release), all three banners of Massachusetts-based Roche Bros. (as announced in a February 24, 2021 press release), and Sprouts Farmers Market (as announced in a March 4, 2021 press release). Approximately 700,000 units of Fit Soda ™ were sold during the product’s first full calendar year of retail sales in 2020 between retail placements in grocery and foodservice outlets, as well as direct-to-consumer sales through the Koios online store. With the addition of Fit Soda ™ to all 1,100 locations of Food Lion across ten U.S. states, the Company believes there is significant opportunity for Fit Soda ™ to have its best year yet in 2021.

Keep reading... Show less